

1 **Impact of Fludrocortisone on the Outcomes of Subarachnoid Hemorrhage Patients: A**
2 **Retrospective Analysis**

3 Akshitkumar M. Mistry, MD¹; Janki Naidugari, BS;² Michael J. Feldman, MD³; Jordan A.
4 Magarik, MD, MS³; Dale Ding, MD¹; Isaac J. Abecassis, MD;¹ Matthew W. Semler, MD, MSc;⁴
5 Todd W. Rice, MD, MSc⁴

6
7 ¹Department of Neurosurgery, University of Louisville, Louisville, KY, USA; ²School of Medicine,
8 University of Louisville, Louisville, KY, USA; ³Department of Neurosurgery, Vanderbilt University
9 Medical Center, Nashville, TN, USA; ⁴Department of Medicine, Division of Allergy, Pulmonary,
10 and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

11

12 **Corresponding Author:**

13 Akshitkumar M. Mistry, MD

14 Department of Neurological Surgery, 220 Abraham Flexner Way, 15th Floor,

15 University of Louisville, Louisville, KY 40202

16 Telephone: 502-407-3226; Fax: 502-582-7477; E-mail: axitamm@gmail.com

17

18 **Funding:** was provided by the Vanderbilt Institute for Clinical and Translational Research
19 (UL1TR000445 and UL1TR002243 from NCATS/NIH).

20 **Short title:** Fludrocortisone improves SAH outcomes

21 **Keywords:** Subarachnoid hemorrhage; Fludrocortisone; Critical Care; Mineralocorticoid

22

23 **Disclosures:** Isaac Abecassis has the following disclosures: 1) Remedy Robotics: Consultant,
24 Equity. 2) IschemaView Inc/Rapid AI: Clinical consultant. 3) Rapid Medical: Consultant. 4) Balt:
25 Consultant. 5) CNS Foundation: Grant Research Support.

26 **ABSTRACT**

27 **Background:** Whether the use of fludrocortisone affects outcomes of patients with aneurysmal
28 subarachnoid hemorrhage (aSAH) and its usage rate in the United States remain unknown.

29 **Methods:** We conducted a retrospective analysis of 78 consecutive patients with a ruptured
30 aSAH at a single academic center in the United States. The primary outcome was the score on
31 the modified Rankin scale (mRS, range, 0 [no symptoms] to 6 [death]) at 90 days. We adjusted
32 the primary outcome for age, hypertension, aSAH grade, and time from aSAH onset to
33 aneurysm treatment. Secondary outcomes were brain and cardiopulmonary dysfunction events.

34 **Results:** Among 78 patients at a single center, the median age was 58 years [IQR, 49 to 64.5];
35 64% were female, and 41 (53%) received fludrocortisone. The adjusted common odds ratio,
36 aOR, of a proportional odds regression model of fludrocortisone use with mRS was 0.33 (95%
37 CI, 0.14-0.80; P=0.02), with values <1.0 favoring fludrocortisone. Organ-specific dysfunction
38 events were not statistically different: delayed cerebral ischemia (22% vs. 39%, P=0.16);
39 cardiac dysfunction (0% vs. 11%; P=0.10); and pulmonary edema (15% vs. 8%; P=0.59).

40 **Conclusions:** The risk of disability or death at 90 days was lower with the use of fludrocortisone
41 in aSAH patients.

42

43 INTRODUCTION

44 Inpatient and overall mortality of patients with aneurysmal subarachnoid hemorrhage
45 (aSAH) are 20% (1-3) and 40%, respectively (4). The high morbidity and mortality result from
46 life-threatening neurological sequelae like re-hemorrhage, cerebral swelling, and vasospasm,
47 which leads to ischemic strokes, as well as non-neurological complications like fatal volume loss
48 from cerebral salt wasting (kidney-driven natriuresis), acute kidney injury (AKI), and
49 cardiopulmonary injury (5-7).

50 Patients with aSAH can have fatal polyuria (>4 liters/day) from natriuresis (8, 9). Thus,
51 they require incredibly large volumes of intravenous fluids to maintain their intravascular volume
52 (8-10). Hence, fluid therapy is the most common therapy aSAH patients receive. In the
53 presence of natriuresis-driven polyuria, fluid administration is among the most considerable
54 challenges in the medical management of aSAH patients. Failure to do so can compromise
55 multi-organ perfusion, increasing the risk of life-threatening ischemic strokes, cardiopulmonary
56 dysfunction, and AKI (11).

57 Fludrocortisone is well-known to reduce natriuresis and hyponatremia, but its effects on
58 outcomes in aSAH patients have not been studied. Using data from a prospective study and two
59 phase 2 randomized controlled trials, we have shown that fludrocortisone decreases natriuresis,
60 hyponatremia, and polyuria in aSAH patients, leading to lower fluid and sodium requirements
61 and hypovolemic incidences (8). Importantly, a meta-analysis of the studies shows that it lowers
62 the rate of symptomatic vasospasm (8). The 2023 American Heart Association aSAH guidelines
63 recommend that “the use of mineralocorticoids is reasonable to treat natriuresis and
64 hyponatremia” (12).

65 However, the impact of fludrocortisone on the clinical outcomes of aSAH patients has
66 yet to be studied. Therefore, to fill this knowledge gap, we conducted a retrospective analysis of
67 aSAH patients enrolled in the SMART randomized trial,(13) comparing outcomes of patients

68 treated with fludrocortisone with those not treated with fludrocortisone. We hypothesized that,
69 because of the established efficacy of fludrocortisone, its use would result in less death or
70 disability, as measured by the modified Rankin Scale (14) (mRS), at 90 days.

71

72 **METHODS**

73 **Study Design and Patient Selection**

74 We conducted a retrospective cohort analysis of all aSAH patients enrolled in the
75 Isotonic Solutions and Major Adverse Renal Events Trial (SMART)(13) after its results and data
76 of aSAH patients were available. SMART was a pragmatic, unblinded, cluster-randomized,
77 multiple-crossover clinical trial (ClinicalTrials.gov: NCT02444988, NCT02547779) conducted at
78 an academic medical center in the United States between June 1, 2015, and April 30, 2017.
79 Trial protocol did not control the use of fludrocortisone. This subanalysis was approved by the
80 institutional review board at Vanderbilt University Medical Center (IRB # 141349).

81

82 **Data Collection**

83 Data for aSAH patients were collected retrospectively blinded to fludrocortisone use. The
84 following co-variables were collected: past medical history (hypertension, diabetes, ischemic
85 heart disease, tobacco use, and prior aSAH); aSAH severity as measured on Hunt and Hess
86 scale, the World Federation of Neurological Surgeons (WFNS) grading system, and the
87 modified Fischer scale; location, largest linear measurement, and treatment procedure
88 (endovascular embolization vs. clip obliteration) of the ruptured aneurysm; time from symptom
89 onset to procedural intervention; new stroke (iatrogenic or spontaneous aneurysmal re-rupture);
90 development of hydrocephalus requiring ventricular cerebrospinal fluid drainage; and infection
91 of the central nervous system, meninges, or cerebrospinal fluid (microbiologically proven or
92 clinical signs treated empirically with 4 or more consecutive days of antibiotics).

93

94 **Study Intervention: Fludrocortisone Administration**

95 The general institutional practice was to maintain euvolemia in aSAH patients and treat
96 electrolyte imbalances. There was no institutional protocol to maintain euvolemia and treat
97 hyponatremia. The use of fludrocortisone (dosage regimen and length), enteral salt, and/or
98 hypertonic saline was provider dependent. Fludrocortisone was frequently initiated in patients
99 with vasospasm who were at risk of hypovolemia. In this cohort, fludrocortisone was started as
100 early as the 3rd day of ICU admission and maintained for the majority of ICU stay.

101

102 **Study Outcomes**

103 Our study outcomes were not part of the SMART trial. Our primary outcome was the
104 ordinal score on the mRS (14) (range, 0 [no symptoms] to 6 [death]) around 90 days. It was
105 collected prospectively as part of routine clinical follow-up. Secondary outcomes included:

- 106 • the 21-day incidence of symptomatic vasospasm (defined as at least a 2-point
107 decrease in Glasgow coma score or 2-point increase in the motor score of the
108 National Institutes of Health Stroke Scale lasting for at least 8 hours after
109 exclusion of attributable cerebral and non-cerebral conditions) and delayed
110 cerebral ischemia (defined as a presence of a new, post-operative hyperintensity
111 on diffusion-weighted magnetic resonance imaging, or a new, permanent focal
112 neurological deficit, or a permanent decrease on Glasgow coma score of at least
113 2 points unattributable to other cerebral and non-cerebral conditions); (15, 16)
- 114 • total amount of fludrocortisone, enteral sodium chloride, and hypertonic saline
115 (3% sodium chloride) received during the hospitalization;
- 116 • cardiac dysfunction defined as myocardial infarction, new onset of heart failure,
117 or initiation of inotropic therapy;

- 118 • pulmonary edema evidenced by a chest radiograph or diuretic treatment with the
119 goal of treating pulmonary edema.

120

121 **Statistical Analysis**

122 Chi-square test for categorical data and the Wilcoxon test for continuous data were
123 utilized for between-group comparisons without adjustment for covariates. The primary analysis
124 compared 90-day mRS scores treated as an ordinal variable between patients treated with and
125 without fludrocortisone using a proportional odds regression model, adjusting for age, history of
126 hypertension, time from aSAH onset to aneurysm treatment, procedure received (clip or
127 embolization), and the WFNS grade at baseline. This outcome was not assessed at the 90-day
128 timepoint in 6 patients; thus for them, the last known mRS score was carried forward. To assess
129 the robustness of the primary analysis, we performed three sensitivity analyses in which we
130 repeated the primary analysis: 1) excluding patients with missing 90-day mRS scores; 2)
131 substituting the mRS scores with values imputed using multivariate imputation by chained
132 equations (mice v3.11 and mitools v2.4 R packages) in which one hundred different datasets
133 were generated with imputed values and results were pooled; 3) any co-variable correlated with
134 fludrocortisone was introduced into the model to adjust its effects; and 4) intervention tested in
135 the SMART trial. The results of the regression models are presented with a point estimate odds
136 ratio and associated 95% confidence interval (CI) range. Significance was set at a two-tailed α
137 ≤ 0.05 . All analyses were performed using R version 4.0.2 software (R Foundation for Statistical
138 Computing, Vienna, Austria).

139

140 **RESULTS**

141 **Baseline Patient Characteristics**

142 The median age of the 78 aSAH patients included in this study was 58 years
143 (interquartile range, IQR, 49 to 64.5) and 50 patients (64%) were female. A total of 70 patients
144 (90%) received an endovascular embolization of their ruptured aneurysm, 46 (59%) of which
145 were in the anterior cerebral circulation. Forty-one patients (53%) were treated with
146 fludrocortisone and 37 patients (47%) were not treated with fludrocortisone. Besides age, which
147 was lower in the group treated with fludrocortisone, the two groups were similar at baseline
148 (Table 1).

149 In the group that received fludrocortisone, the median dosage and the number of
150 patients treated per ICU admission day are plotted in Figure 1. More patients treated with
151 fludrocortisone were also co-treated with enteral salt [13 (32%) vs. 6 (16%); $P=0.12$] and
152 hypertonic saline [23 (56%) vs. 6 (16%); $P<0.01$]. When used, the amount of enteral salt and
153 hypertonic saline did not significantly differ between groups (Table 2).

154

155 **Outcomes**

156 Compared with patients who did not receive fludrocortisone, patients who received
157 fludrocortisone experienced a lower mRS scores at 90 days (adjusted common odds ratio, aOR,
158 of 0.33; 95% CI, 0.14 to 0.80; $P=0.02$), with values below 1.0 favoring receipt of fludrocortisone
159 (Figure 2; Table 3). Excluding the 6 patients who did not have a mRS score at 90 days resulted
160 in an aOR of 0.36 (95% CI, 0.14 to 0.92; $P=0.03$). Substituting them with imputed values
161 resulted in an aOR of 0.36 (95% CI, 0.14 to 0.91; $P=0.04$). Because the use of enteral salt and
162 hypertonic saline correlated with the use of fludrocortisone (Table 3), we introduced these
163 variables in the regression model. Both did not independently correlate with the outcomes (use
164 of enteral salt aOR 0.5 [0.18-1.35]; $P=0.17$; and use of hypertonic saline aOR 1.30 [0.45-3.70];
165 $P=0.63$), but the use of fludrocortisone maintained a similar association as in the primary
166 analysis (aOR 0.41 [0.15-1.04]; $P=0.06$). Because these patients were enrolled in the SMART

167 trial, comparing the primary use of balanced crystalloids to saline for intravenous fluid therapy,
168 we included the trial fluid assignment as an interaction variable in the model. Of the 41 patients
169 who received fludrocortisone, 21 were assigned saline and 20 were assigned a balanced
170 crystalloid; and of the 37 patients who did not receive fludrocortisone, 20 were assigned saline
171 and 17 were assigned a balanced crystalloid. In this model, the use of fludrocortisone continued
172 to maintain a similar association as in the primary analysis (aOR 0.15 [0.04-0.60]; P=0.01). The
173 use of saline was associated with better outcomes (aOR 0.24 [0.06-0.96]; P=0.05). Importantly,
174 in the model the interaction term of fluid assignment and fludrocortisone did not associate with
175 outcome (aOR 3.22 [0.50-21.6]; P=0.22).

176 Patients treated with or without fludrocortisone experienced similar incidences of organ
177 dysfunction events (Table 4). Patients treated with fludrocortisone had higher but not statistically
178 significant incidences of symptomatic vasospasm [17 (42%) vs 8 (22%); P=0.10], delayed
179 cerebral ischemia events [17 (42%) vs 8 (22%); P=0.16], and pulmonary edema [6 (15%) vs 3
180 (8%); P=0.59]. No patient with fludrocortisone had cardiac dysfunction (0 (0%) vs 4 (11%);
181 P=0.10). Length of hospital stay did not differ with the use of fludrocortisone (median 17 days
182 [IQR 14-22] vs 16 [11-20]; Table 4).

183

184 **DISCUSSION**

185 The 2023 American Heart Association aSAH guidelines recommend that “the use of
186 mineralocorticoids is reasonable to treat natriuresis and hyponatremia,”(12) citing its efficacy
187 from randomized controlled trials (8). Natriuresis-driving hypovolemia can compromise organ
188 perfusion, risking life-threatening ischemic strokes (in the setting of cerebral vasospasm), AKI,
189 and cardiopulmonary dysfunction (11). Indeed, a meta-analysis showed that fludrocortisone
190 reduces symptomatic vasospasm in aSAH patients (8). A 8346-patient population-based study
191 showed that poor hemodynamic status (hyponatremia and hypovolemia) increases the risk of

192 adverse events from vasospasm (17) resulting in poor outcomes. A similar therapeutic effect of
193 fludrocortisone has been observed in patients with TB meningitis who also exhibit natriuresis-
194 driven hypovolemia and strokes (18). However, its impact on outcomes of aSAH patients is
195 unclear and has not been reported since 1999 (19). In this retrospective study, we found that
196 fludrocortisone therapy was independently associated with better outcomes following aSAH.

197 The results of our study must be interpreted within its limitations. First, this study has
198 inherent retrospective bias. Second, the effect size we observed is large and may be due to the
199 study's small sample size. The sample size was selected based on the identification and
200 selection of a *consecutive* cohort of aSAH patients, which was facilitated by the SMART trial.
201 Third, conduct at a single center limits generalizability. Fourth, fludrocortisone was not
202 protocolized and was often started by some providers after the patient exhibited symptomatic
203 vasospasm and hypovolemia, weakening any causal link between the outcomes and
204 fludrocortisone. Thus, the higher rate of symptomatic vasospasm and delayed cerebral ischemia
205 seen in the group treated with fludrocortisone should be interpreted with great caution. All prior
206 studies, including randomized controlled trials, have shown fludrocortisone is associated with
207 lower incidences of symptomatic vasospasm and delayed cerebral ischemia (8). However, it is
208 noteworthy that despite greater incidences of symptomatic vasospasm and delayed cerebral
209 ischemia, the use of fludrocortisone in these patients was associated with better outcomes. Our
210 results must be confirmed with prospective randomized controlled trials.

211

212 **CONCLUSIONS**

213 In this retrospective cohort analysis, the use of fludrocortisone was associated with
214 better outcomes in aSAH patients. This finding must be confirmed with a randomized controlled
215 trial.

216

217 **REFERENCES**

- 218 1. Chan V, Lindsay P, McQuiggan J, et al. Declining Admission and Mortality Rates for
219 Subarachnoid Hemorrhage in Canada Between 2004 and 2015. *Stroke* 2019;50:181-184.
- 220 2. Lee VH, Ouyang B, John S, et al. Risk stratification for the in-hospital mortality in
221 subarachnoid hemorrhage: the HAIR score. *Neurocrit Care* 2014;21:14-19.
- 222 3. Stienen MN, Germans M, Burkhardt JK, et al. Predictors of In-Hospital Death After
223 Aneurysmal Subarachnoid Hemorrhage: Analysis of a Nationwide Database (Swiss SOS [Swiss
224 Study on Aneurysmal Subarachnoid Hemorrhage]). *Stroke* 2018;49:333-340.
- 225 4. Nieuwkamp DJ, Setz LE, Algra A, et al. Changes in case fatality of aneurysmal subarachnoid
226 haemorrhage over time, according to age, sex, and region: a meta-analysis. *Lancet Neurol*
227 2009;8:635-642.
- 228 5. Chen S, Li Q, Wu H, et al. The harmful effects of subarachnoid hemorrhage on extracerebral
229 organs. *Biomed Res Int* 2014;2014:858496.
- 230 6. Lantigua H, Ortega-Gutierrez S, Schmidt JM, et al. Subarachnoid hemorrhage: who dies, and
231 why? *Crit Care* 2015;19:309.
- 232 7. Solenski NJ, Haley EC, Jr., Kassell NF, et al. Medical complications of aneurysmal
233 subarachnoid hemorrhage: a report of the multicenter, cooperative aneurysm study. Participants
234 of the Multicenter Cooperative Aneurysm Study. *Crit Care Med* 1995;23:1007-1017.
- 235 8. Mistry AM, Mistry EA, Ganesh Kumar N, et al. Corticosteroids in the Management of
236 Hyponatremia, Hypovolemia, and Vasospasm in Subarachnoid Hemorrhage: A Meta-Analysis.
237 *Cerebrovasc Dis* 2016;42:263-271.
- 238 9. Mistry AM, Magarik JA, Feldman MJ, et al. Saline versus Balanced Crystalloids for Adults
239 with Aneurysmal Subarachnoid Hemorrhage: A Subgroup Analysis of the SMART Trial. *Stroke*
240 *Vasc Interv Neurol* 2022;2.

- 241 10. Barlow B, Thompson Bastin ML, Shadler A, et al. Association of chloride-rich fluids and
242 medication diluents on the incidence of hyperchloremia and clinical consequences in
243 aneurysmal subarachnoid hemorrhage. *J Neurocrit Care* 2022;15:113-121.
- 244 11. Brown RJ, Epling BP, Staff I, et al. Polyuria and cerebral vasospasm after aneurysmal
245 subarachnoid hemorrhage. *BMC Neurol* 2015;15:201.
- 246 12. Hoh BL, Ko NU, Amin-Hanjani S, et al. 2023 Guideline for the Management of Patients With
247 Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart
248 Association/American Stroke Association. *Stroke* 2023;54:e314-e370.
- 249 13. Semler MW, Self WH, Wanderer JP, et al. Balanced Crystalloids versus Saline in Critically Ill
250 Adults. *N Engl J Med* 2018;378:829-839.
- 251 14. van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the
252 assessment of handicap in stroke patients. *Stroke* 1988;19:604-607.
- 253 15. Vergouwen MD, Vermeulen M, van Gijn J, et al. Definition of delayed cerebral ischemia after
254 aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational
255 studies: proposal of a multidisciplinary research group. *Stroke* 2010;41:2391-2395.
- 256 16. Rosengart AJ, Schultheiss KE, Tolentino J, et al. Prognostic factors for outcome in patients
257 with aneurysmal subarachnoid hemorrhage. *Stroke* 2007;38:2315-2321.
- 258 17. Rumalla K, Lin M, Ding L, et al. Risk Factors for Cerebral Vasospasm in Aneurysmal
259 Subarachnoid Hemorrhage: A Population-Based Study of 8346 Patients. *World neurosurgery*
260 2021;145:e233-e241.
- 261 18. Misra UK, Kalita J, Kumar M. Safety and Efficacy of Fludrocortisone in the Treatment of
262 Cerebral Salt Wasting in Patients With Tuberculous Meningitis: A Randomized Clinical Trial.
263 *JAMA Neurol* 2018;75:1383-1391.

264 19. Mori T, Katayama Y, Kawamata T, et al. Improved efficiency of hypervolemic therapy with
265 inhibition of natriuresis by fludrocortisone in patients with aneurysmal subarachnoid
266 hemorrhage. J Neurosurg 1999;91:947-952.

267

268 **Table 1. Patient characteristics at baseline.**
269

Patient characteristics ^a	No Fludrocortisone (n=37)	Fludrocortisone (n=41)	P value ^b
Age, median [IQR], yrs	61 [53-67]	55 [49-62]	0.04
Men, n (%)	12 (32%)	17 (42%)	0.56
Chronic comorbidities, n (%)			
Ischemic heart disease	2 (5%)	5 (12%)	0.52
Active tobacco smoking	12 (32%)	20 (49%)	0.22
Hypertension	31 (84%)	29 (71%)	0.27
Diabetes	5 (14%)	3 (7%)	0.60
Prior subarachnoid hemorrhage	2 (5%)	0 (0%)	0.43
Subarachnoid hemorrhage severity			
WFNS grade			0.72
Grade 1	7 (19%)	12 (29%)	
Grade 2	10 (27%)	12 (29%)	
Grade 3	3 (8%)	4 (10%)	
Grade 4	9 (24%)	6 (15%)	
Grade 5	8 (22%)	7 (17%)	
Hunt Hess score			0.47
Grade 1	0 (0%)	0 (0%)	
Grade 2	11 (30%)	14 (34%)	
Grade 3	9 (24%)	15 (37%)	
Grade 4	11 (30%)	8 (20%)	
Grade 5	6 (16%)	4 (10%)	
modified Fischer score			0.56
Score 1	1 (3%)	1 (2%)	
Score 2	3 (8%)	7 (17%)	
Score 3	8 (22%)	11 (27%)	
Score 4	25 (68%)	22 (54%)	
Aneurysm location, n (%)			>0.99
Anterior circulation	22 (59%)	24 (59%)	
Posterior circulation	15 (41%)	17 (41%)	
Aneurysm size, median [IQR], mm	4.6 [4.0-6.4]	5.4 [4.0-8.2]	0.22
Treatments received			0.60
Clip obliteration, n (%)	5 (14%)	3 (7%)	
Endovascular embolization, n (%)	32 (86%)	38 (93%)	
Time from symptom onset to surgical treatment, median [IQR], days	1.46 [1.00-4.46]	1.54 [1.34-2.42]	0.82
CNS complications, n (%)			
Aneurysm re-rupture	1 (3%)	0 (0%)	0.96
Secondary open operation ^c	4 (11%)	0 (0%)	0.10
Iatrogenic stroke	3 (8%)	0 (0%)	0.20
Ventricular CSF diversion	24 (65%)	30 (73%)	0.58
CNS infection ^d	1 (3%)	4 (10%)	0.42

270 ^aAbbreviations: CSF – cerebrospinal fluid; CNS – central nervous system; ICU – intensive care
271 unit; IQR – interquartile range; WFNS – world federation of neurological surgeons

272 ^bStatistical tests: Group differences were tested with a Chi-square test for categorical variables
273 and Wilcoxon test for continuous variables.

274 ^cSecondary open operation defined as craniotomy or craniectomy after completion for treatment
275 of the aneurysm.

276 ^dCNS infection defined as infection of the central nervous system, meninges, or cerebrospinal
277 fluid (microbiologically proven or clinical signs treated empirically with 4 or more consecutive
278 days of antibiotics).

279 **Table 2. Sodium supplementation between ICU admission and day 14 in aSAH patients**
280 **treated with and without fludrocortisone.**

281

Sodium Replacement^a	Fludrocortisone (n=41)	No Fludrocortisone (n=37)	P value
Hypertonic saline			
median [IQR], mL	4500 [1000-6000]	1625 [1062.50-5187.50]	0.79
n	13 (32%)	6 (16%)	0.12
Enteral salt			
median [IQR], g	14 [6-47.5]	11.5 [7.25-16.5]	0.40
n	23 (56%)	6 (16%)	<0.01

282 ^aAbbreviations: aSAH – aneurysmal subarachnoid hemorrhage; ICU – intensive care unit; IQR –
283 interquartile range

284 **Table 3. Ordinal regression models for 90-day modified Rankin Scale (mRS) scores.**
285 Adjusted common odds ratios with 95% confidence intervals and corresponding P values are
286 reported.
287

Co-variable	Effect size
Fludrocortisone (vs. no fludrocortisone)	0.33 [0.14-0.80], P=0.02
Age (continuous)	1.06 [1.02-1.10], P=0.01
Time to treatment (continuous)	1.00 [0.91-1.10], P=0.96
Hypertension (no hypertension as reference)	1.20 [0.44-3.31], P=0.72
Endovascular embolization (clip obliteration as reference)	1.01 [0.21-4.80], P=0.99
World Federation of Neurological Surgeon's grade (Grade 1 as reference)	
Grade 2	2.27 [0.67-7.88], P=0.19
Grade 3	4.70 [0.92-24.7], P=0.06
Grade 4	5.36 [1.50-20.2], P=0.01
Grade 5	18.7 [4.78-79.0], P<0.01

288

289 **Table 4. Outcomes**
290

Outcome^a	No Fludrocortisone (n=37)	Fludrocortisone (n=41)	Adjusted common odds ratio (95% CI)	P value^c
Primary outcome				
mRS at 90 days, <i>n</i>	3 [2-4]	1 [1-2]	0.33 [0.14-0.80] ^b	0.02
Secondary outcomes				
<i>Clinical outcomes, n (%)</i>				
Length of stay, days	16 [11-20]	17 [14-22]		0.39
<i>Adverse organ-based events, n (%)</i>				
Symptomatic vasospasm	8 (22%)	17 (42%)	-	0.10
Delayed cerebral ischemia	8 (22%)	16 (39%)	-	0.16
Pulmonary edema ^d	3 (8%)	6 (15%)	-	0.59
Cardiac dysfunction ^e	4 (11%)	0 (0%)	-	0.10

291 ^aAbbreviations: CI – confidence interval; mRS – modified Rankin Scale

292 ^bAdjusted common odds ratio from a proportional odds regression analysis

293 ^cGroup differences were tested with a Chi-square test for categorical variables and Wilcoxon
294 test for continuous variables; if odds ratios are presented, associated P values are presented

295 ^dPulmonary edema evidenced by a chest radiograph and/or initiation of a diuretic treatment with
296 the goal of treating pulmonary edema.

297 ^eCardiac dysfunction defined as myocardial infarction, new onset of heart failure, or initiation of
298 inotropic therapy.


299 **FIGURE LEGENDS**

300 **Figure 1. Fludrocortisone use in aneurysmal subarachnoid hemorrhage patients.** The
301 median dose of fludrocortisone (blue line) with interquartile range (light blue shade) and the
302 number of patients treated with fludrocortisone (red line) are plotted against the post-
303 subarachnoid hemorrhage day.

304

305

306 **Figure 2. Functional outcomes of patients with aneurysmal subarachnoid hemorrhage**
307 **treated with and without fludrocortisone.** Distribution of scores on the modified Rankin scale
308 (mRS) at 90 days according to the treatment with fludrocortisone. The mRS ranges from a score
309 of 0, indicating no symptoms, to a score of 6, indicating death. The numbers within the bars are
310 percentages of patients who attained the score.



90-day mRS 0 1 2 3 4 5 6

